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IL-27, a member of the IL-12 cytokine family, primes Th1 cell differentiation, whereas it suppresses Th17 cell
development. We have previously reported that serum IL-27 levels are elevated in psoriatic patients and that
IL-27 greatly induces in vitro production of Th1-type chemokines through STAT1 activation. In this study, to
further investigate the in vivo role of IL-27 in the pathogenesis of psoriasis, we induced psoriasis-like
inflammation on mouse back skin with topical application of imiquimod (IMQ), and continuously injected IL-27
or PBS subcutaneously. IMQ-treated skin showed an increase of IL-27 mRNA levels and the infiltration of IL-27-
producing cells in the papillary dermis. The injection of IL-27 to the IMQ-treated skin exacerbated the disease
compared with PBS injection. The IL-27 injection further augmented mRNA levels of IFN-g, CXCL9, CXCL10,
CXCL11, and TNF-a, without altering those of IL-17A, IL-17F, IL-22, and CCL20. Finally, IL-27 antagonism
attenuated the upregulation of IFN-g, CXCL9, CXCL10, CXCL11, and TNF-amRNA levels, and induced clinical and
histological improvement in the IMQ-treated skin. These results indicate that IL-27 would act in a
proinflammatory manner, and thereby exacerbate the psoriasis-like skin inflammation induced by IMQ.
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INTRODUCTION
Psoriasis is a chronic inflammatory dermatosis characterized
by epidermal hyperproliferation and inflammation with a
marked infiltration of dendritic cells (DCs), T cells, neutro-
phils, and macrophages (Lowes et al., 2007). Plasmacytoid
DCs, one of the effector cells of innate immunity in psoriatic
lesions, once triggered by Toll-like receptor agonists,
produce high levels of IFN-a, which activates dermal DCs
and triggers downstream T cell–mediated adaptive immunity
(Nestle et al., 2005). The activated dermal DCs, after
migration from skin to lymph nodes, differentiate naive
T cells into T-helper 1 (Th1) cells or Th17 cells through IL-12
or IL-23, respectively (Lowes et al., 2007). Psoriatic inflam-
mation was initially considered to be mediated by Th1 cells
producing IFN-g. However, it is increasingly recognized
that immune responses by Th17 cells producing IL-17 or
IL-22 also contribute to the pathogenesis of psoriasis (Lowes
et al., 2007).
IL-27, a member of the IL-12 cytokine family, is a recently
discovered cytokine consisting of p28 and Epstein–Barr
virus–induced gene protein 3 subunits (Batten and Ghilardi,
2007). IL-27 has been reported to exhibit diverse functions
during T-cell differentiation and immune responses. Initial
reports described that IL-27 promotes Th1 differentiation from
naive T cells through signal transducer and activator of
transcription (STAT) 1–dependent pathway (Takeda et al.,
2003; Owaki et al., 2005). Subsequent studies have reported
that IL-27 rather suppresses Th17 development and immune
responses (Yoshimura et al., 2006; Kastelein et al., 2007;
Diveu et al., 2008; Stumhofer and Hunter, 2008).
The significance of IL-27 has been reported in so-called
Th1/Th17-mediated inflammatory diseases, which were once
considered as Th1-type and now increasingly recognized as
Th17-type, including psoriasis, rheumatoid arthritis, multiple
sclerosis, and inflammatory bowel diseases (Honda et al.,
2005; Schmidt et al., 2005; Batten et al., 2006; Fitzgerald
et al., 2007; Cao et al., 2008; Niedbala et al., 2008).
However, it still remains controversial whether the increase
of IL-27 indicates its proinflammatory role to activate Th1
cells or whether it is a sign of regulatory mechanism to limit
Th17 cell activity (Honda et al., 2005; Batten et al., 2006;
Cao et al., 2008; Niedbala et al., 2008).
We recently reported the importance of IL-27 in the
pathogenesis of psoriasis (Shibata et al., 2010). Serum IL-27
levels in psoriatic patients are significantly higher than those
in healthy controls, and correlate with the disease severity
and serum IFN-g levels. Furthermore, immunohistochemical
analyses reveal the infiltration of IL-27-positive cells in the
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papillary dermis of psoriatic skin lesions. IL-27 alone greatly
induces chemokine (C-X-C motif) ligand (CXCL)9, CXCL10,
and CXCL11 production, and tyrosine phosphorylation of
STAT1 in normal human keratinocytes. Others showed
similar results with the additional data that IL-27 induces
STAT3 phosphorylation in keratinocytes (Wittmann et al.,
2009). These data supported the idea that IL-27 might exacer-
bate psoriasis. However, at the same time, IL-27 suppresses
the tumor necrosis factor (TNF)-a-induced production of
IL-1a and CCL20 by keratinocytes in vitro.
These contradictory data have led us to further investigate
the in vivo role of IL-27 during the development of psoriasis
and to determine its pathophysiological significance. Imiqui-
mod (IMQ)-induced psoriasis-like skin inflammation is a
recently reported rodent model of psoriasis (van der Fits et al.,
2009). In this model, mice are treated with topical IMQ, a
Toll-like receptor 7/8 agonist, on the shaved back skin for 6
consecutive days. IMQ activates plasmacytoid DCs and
triggers downstream Th1 and Th17 cell–mediated adaptive
immunity, and accordingly, mice gradually exhibit thick
skin with erythema and scales. These clinical features start
appearing after 4 days of IMQ treatment and aggravate up
until 6 days. Recently, various studies using this model have
been reported to explore immunological significance of
psoriasis (Cai et al., 2011; Ishizaki et al., 2011; Van Belle
et al. 2012). This model would now be one of the established
rodent models for psoriasis, sharing pathogenic and
immunological features with psoriasis. We investigated the
in vivo role of IL-27 in the pathogenesis of psoriasis and
explored the underlying mechanism using this rodent model
of psoriasis.
RESULTS
IMQ application or IL-23 injection to the mouse back or ear
skin induced the upregulation of IL-27 mRNA levels and
infiltration of IL-27-positive cells
We previously found that IL-27-positive cells infiltrate in the
papillary dermis of human psoriatic skin lesions (Shibata et al.
2010). To investigate whether IL-27 is also expressed in IMQ-
or IL-23-treated skin, we performed quantitative real-time
PCR analysis of the skin isolated at day 0, 2, 4, and 6 of IMQ
treatment, and at day 0, 7, and 13 of IL-23 injection. Both
IL-27p28 and Epstein–Barr virus–induced gene 3 mRNA
expression levels increased gradually (Figure 1a and c), and
thus, we also performed immunohistochemical staining of
IL-27. IL-27-positive cells were found among the infiltrating
cells in the papillary dermis of IMQ- or IL-23-treated skin,
whereas they were not detected in control Vaseline-treated
or PBS-injected skin (Figure 1b and d). In this study, we
determined to focus on the imiquiod application model.
Antigen-presenting cells, especially DCs, are the primary
sources of IL-27 in the IMQ-treated psoriasis-like skin lesions
To investigate the cell source for IL-27, we performed
immunofluorescent double staining with IL-27 monoclonal
antibody and antibodies against antigen-presenting cells
(major histocompatibility complex (MHC) class II), DCs
(CD11c), T cells (CD3), and mast cells (CD117). We observed
colocalization of IL-27 with MHC class II and CD11c, but not
with CD3 or CD117 (Figure 2), indicating that antigen-
presenting cells, especially DCs, would be the primary
sources of IL-27.
IL-27 injection exacerbated the IMQ-induced psoriasis-like skin
inflammation with more severe epidermal hyperplasia and
inflammatory cell infiltrates
As IL-27 was highly expressed in the IMQ-treated skin and
thus supposed to be involved in the development of psoriasis,
we next continuously injected IL-27 or PBS subcutaneously,
together with IMQ or Vaseline treatment. Both PBS- and
IL-27-injected mice with Vaseline treatment showed no
phenotypical or histological changes (Figure 3a–c). Mice
with IMQ treatment gradually mimic the phenotype of
psoriasis with erythema, thickness, and scales (Figure 3a).
IL-27-injected mice of IMQ treatment exhibited worse
clinical outcome with more severe scales and thicker skin
compared with PBS-injected mice of IMQ treatment
(Figure 3a). Significant differences in the disease severity
were observed between mice injected with IL-27 and PBS
from day 4 to 6 (Figure 3b). Consistent with clinical scores,
histological analyses of skin samples at day 6 of IMQ
treatment revealed more severe epidermal hyperplasia with
elongation of rete ridges and more intense inflammatory cell
infiltrates in IL-27-injected mice as compared with PBS-
injected mice (Figure 3c). Thus, IL-27 injection exacerbated
dermatitis in the IMQ-treated skin clinically and pathologi-
cally.
IL-27 injection enhanced mRNA levels of Th1 cytokine/
chemokines and TNF-a in the IMQ-treated psoriasis-like skin
lesions
We next examined the effect of the IL-27 injection on mRNA
levels of genes involved in the development of psoriasis. The
murine back skin samples were isolated at day 2 of IMQ or
Vaseline treatment together with IL-27 or PBS injection, and
their mRNA levels were analyzed using real-time PCR. IL-27
injection alone did not affect gene expression levels of
cytokines and chemokines as compared with PBS injection
in Vaseline-treated skin (Figure 4a–c). Compared with
control Vaseline-treated skin, IMQ-treated skin revealed
increased mRNA levels of genes regarding Th1 and Th17
responses in psoriasis, IFN-g/CXCL9/CXCL10/CXCL11
(Figure 4a) and IL-17A/IL-17F/IL-22/CCL20 (Figure 4b),
respectively, and of TNF-a (Figure 4c), a key cytokine for
the acceleration of psoriasis. IL-27 injection further aug-
mented the mRNA levels of IFN-g/CXCL9/CXCL10/CXCL11
(Figure 4a) and of TNF-a (Figure 4c) as compared with
PBS injection in IMQ-treated skin. However, mRNA levels
of IL-17A/IL-17F/IL-22/CCL20 did not differ significantly
between the IL-27- and PBS-injected mice of IMQ applica-
tion (Figure 4b). These results support the established
concept that IL-27 preferentially induces Th1 differentiation
but not that of Th17 (Takeda et al., 2003; Owaki et al.,
2005), and suggest that IL-27 might accelerate the progres-
sion of psoriasis by inducing Th1-type cytokine/chemokines
and TNF-a.
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IL-27 in vitro upregulated the LPS-induced production of TNF-a
by peritoneal macrophages
Next, we evaluated the in vitro effects of IL-27 on the
production of TNF-a using peritoneal macrophages.
Although IL-27 alone did not induce TNF-a production, it
dose dependently enhanced lipopolysaccharide (LPS)-
induced production of TNF-a by macrophages in vitro
(Figure 5). We also investigated the effect of IL-27 on the
production of TNF-a by keratinocytes; however, TNF-a
production by keratinocytes did not change after IL-27
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Figure 1. IL-27 mRNA levels and infiltration of IL-27-positive cells during the imiquimod (IMQ) application and IL-23 injection. (a) IL-27 mRNA expression
levels in IMQ-induced psoriasis-like skin inflammation. Quantitative real-time PCR analysis of IL27p28 and Epstein–Barr virus–induced gene 3 (EBI3) mRNAs in
the IMQ-treated skin. Total RNA was isolated from mouse back skin at day 0, 2, 4, and 6 of IMQ treatment. Data were obtained from duplicate samples from at
least three mice on each day. Values are presented as means±SEs (n¼6). (b) The immunohistochemical analyses for IL-27-positive cells after 6 days of IMQ
treatment. The left and middle panels show IL-27 staining of intermediate-power view ( 200) and high-power view ( 400), respectively, in IMQ-treated skin.
The right panel shows staining with isotype-matched control IgG of intermediate-power view ( 200) in IMQ-treated skin. The arrows indicate IL-27-positive
cells. The results are representative of six separate experiments. Bar¼ 20mm. (c) Quantitative real-time PCR analysis of IL27p28 and EBI3 mRNAs in the IL-23-
injected skin. Total RNA was isolated from mouse ear skin at day 0, 7, and 13 of IL-23 injection. Data were obtained from duplicate samples from at least three
mice on each day. Values are presented as means±SEs (n¼6). (d) The immunohistochemical analyses for IL-27-positive cells at day 13 of IL-23 injection. The
left and middle panels show IL-27 staining of IL-23- and PBS-injected skin, respectively ( 400). The right panel shows staining with isotype-matched control
IgG of IL-23-injected skin (200). The arrows indicate IL-27-positive cells. The results are representative of six separate experiments. Bar¼20 mm.
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stimulation (Supplement Figure S1 online). Taken together
with the in vivo results of IL-27-injected mice (Figure 4c),
IL-27 may enhance TNF-a expression both in vitro and
in vivo.
IL-27 antagonism induced clinical and histological
improvement in the IMQ-treated psoriasis-like skin lesions
Finally, to evaluate whether IL-27 antagonism attenuates
the progression of psoriasis, we intraperitoneally injected
anti-IL-27p28 antibody or control IgG immediately before
(day 0) and 3 days after the IMQ treatment (day 3). IL-27
antibody–injected mice exhibited improvement in the
severity scores at day 5 and day 6, as compared with
control IgG–injected mice (Figure 6a and b). Consistent
with the clinical scores, there was significant improve-
ment in epidermal thickness and in the number of
inflammatory cell infiltrates in IL-27 antibody–injected
mice (Figure 6c).
IL-27 antagonism attenuated the upregulation of IFN-c, CXCL9,
CXCL10, CXCL11, and TNF-a mRNA levels in the IMQ-treated
psoriasis-like skin lesions
We also determined the mRNA levels of Th1 and Th17
cytokine/chemokines and TNF-a in the IMQ-treated skin of
IL-27 antibody or control IgG injection. These mRNA
levels were comparable in mice injected with control IgG
and anti-IL-27 antibody at day 2 of IMQ treatment (data not
shown). At day 6, however, mRNA expression levels of
IFN-g/CXCL9/CXCL10/CXCL11 (Figure 7a) and TNF-a
(Figure 7c) were significantly reduced in IL-27 antibo-
dy–injected mice compared with control IgG–injected
mice. By contrast, mRNA levels of IL-17A/IL-17F/IL-22/
CCL20 were not affected by treatment with IL-27 antibody
(Figure 7b). These results indicate that endogenous IL-27
might contribute to the expression of Th1 cytokine/
chemokines and TNF-a in IMQ-induced psoriasis-like skin
lesions.
IL-27 Overlay MHC class II
APCs
IL-27 Overlay CD11c
DCs
IL-27 Overlay CD3
IL-27 Overlay CD117
CD117
CD3
Figure 2. Colocalization of IL-27 with antigen-presenting cells (APCs) and dendritic cells (DCs). Imiquimod-treated skin was subjected to dual-color
immunofluorescence staining for IL-27 (green, the left four panels) and major histocompatibility complex (MHC) class II, CD11c, CD3, or CD117 (red, the right
four panels;  400). The overlay images are shown in the middle four panels ( 400). The arrows indicate the colocalization of IL-27 with MHC class II and
CD11c. Bar¼ 20 mm.
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DISCUSSION
This study demonstrated that IL-27, a dual regulator of T-cell
immune responses, accelerated the disease progression of
IMQ-induced psoriasis-like skin lesions. We first showed that
IL-27-secreting cells, which are detected in human psoriatic
skin lesions in our previous report (Shibata et al. 2010), were
also present in the skin lesions of the two representative
rodent models for psoriasis, IMQ application and IL-23
injection models. IL-27 injection to the IMQ-treated skin
further exacerbated the disease phenotype and increased
mRNA levels of Th1 cytokine/chemokines and TNF-a without
altering those of Th17 cytokine/chemokines. In addition,
IL-27 in vitro upregulated LPS-induced TNF-a production
by peritoneal macrophages. Accordingly, the neutraliza-
tion of IL-27 during the IMQ treatment reduced the mRNA
levels of Th1 cytokine/chemokines and TNF-a, and
induced clinical and histological improvements. Our
report indicates the in vivo involvement of IL-27 in the
pathogenesis of psoriasis, and to our knowledge, this is
previously unreported.
Although psoriasis was initially considered as a Th1-
mediated disease, its importance has been underestimated
ever since the discovery of Th17 cells, a third subset of Th
cells producing IL-17 (Lowes et al., 2007). However, IFN-g
levels are augmented in serum and skin lesions of psoriasis
patients (Austin et al., 1999; Szegedi et al., 2003; Arican
et al., 2005), which indicates a shift toward Th1 immune
responses in patients’ peripheral blood, as well as in skin
lesions. IFN-g, in synergy with TNF-a, induces the production
of various proinflammatory cytokines and chemokines, such
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Figure 3. The exacerbation of imiquimod (IMQ)-induced psoriasis-like skin inflammation by IL-27 injection. (a) Phenotypical presentation (the left four panels)
and histological analyses of mouse back skin (the right four panels) are shown. In each group, mice were injected with PBS or IL-27 and Vaseline or IMQ was
applied. Bar¼ 20mm. (b) Clinical scores during IMQ treatment. Erythema, scaling, and thickness of the back skin were scored on a scale from 0 to 4, and these
scores were accumulated from 3 to 5 mice per group. Data are presented as means±SEs (n¼5). *Po0.05 versus PBS-injected mice with IMQ application.
(c) Epidermal thickness and the number of inflammatory cell infiltrates in the dermis at day 6 of IMQ treatment. Numbers of epidermal cell layers and
dermal inflammatory cells were counted per high-power field from three to five mice per group. Data are presented as means±SEs (n¼6). ***Po0.001
versus PBS-injected and ###Po0.001 versus IL-27-injected mice with Vaseline application, respectively. H&E, hematoxylin and eosin.
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as IL-6, IL-8, and IL-1, by epidermal keratinocytes, and these
cytokines and chemokines further activate T cells, macro-
phages, and neutrophils, which would contribute to the
development of psoriasis (Bonifati and Ameglio, 1999;
Guenther and Ortonne, 2002; Prinz, 2003). In addition, the
expression of Th1 chemokines CXCL9/CXCL10/CXCL11,
which promotes the recruitment of Th1 cells, is upregulated
in the keratinocytes of psoriatic skin lesions (Gottlieb et al.,
1988; Flier et al., 1999, 2001; Giustizieri et al., 2001). Taken
together with these previous reports, the enhanced expression
of IFN-g, CXCL9, CXCL10, and CXCL11 by IL-27 injection to
IMQ-treated skin suggests that IL-27 may promote Th1-type
inflammation in psoriatic skin lesions and exacerbate the
disease, which lead us to reconfirm the importance of Th1
responses in the development of psoriasis.
Regulatory properties of IL-27 have been reported in
several animal models of Th1/Th17-mediated inflammatory
diseases (Honda et al., 2005; Batten et al., 2006; Amadi-Obi
et al., 2007; Cao et al., 2008; Niedbala et al., 2008). In this
study, IL-27 did not suppress the expression of Th17
cytokines and chemokines, such as IL-17A, IL-17F, IL-22,
and CCL20. This might be explained by the function of TNF-a
on Th17 responses. Th17 cells can be activated by TNF-a,
and the inhibition of TNF-a reduces Th17 responses in
psoriatic patients (Iwamoto et al., 2007; Zaba et al., 2007).
Thus, in the IMQ-induced psoriatic skin lesions, the putative
direct suppression of Th17 responses via IL-27 might be
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Figure 4. Quantitative real-time PCR analysis of control Vaseline- or imiquimod (IMQ)-treated skin with PBS or IL-27 injection. PBS- or IL-27-injected mice
were treated daily with IMQ or control Vaseline on back skin, and mRNA levels were determined at day 2 by quantitative real-time PCR for T-helper 1 (Th1)
cytokine/chemokines (a), Th17 cytokine/chemokines (b), and tumor necrosis factor (TNF)-a (c). Data were obtained from duplicate samples from five to eight
mice in each group. Values are presented as means±SEs (n¼ 10 to 16). *Po0.05 and **Po0.01 versus PBS-injected mice with Vaseline application, and
#Po0.05 and ##Po0.01 versus IL-27-injected mice with Vaseline application, respectively.
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Figure 5. Effects of IL-27 on the in vitro production of tumor necrosis factor
(TNF)-a in peritoneal macrophages. Thioglycollate-elicited peritoneal
macrophages were treated with the indicated concentrations of IL-27 alone
for 24 hours or were pretreated with IL-27 for 12 hours, followed by treatment
with lipopolysaccharide (LPS) (10 ngml1) for another 24 hours. TNF-a levels
in supernatants were determined using ELISA kits. Data are means±SEs
(n¼4) and are representative of three independent experiments.
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compensated by the activation of Th17 cells via TNF-a,
whose expression is enhanced by IL-27.
Recently, Li et al. (2011) have demonstrated the important
role of IL-27 in aplastic anemia via TNF-a induction. They
found that increased serum IL-27 levels correlate with the
disease severity of aplastic anemia and that recombinant
human IL-27 enhances the production of TNF-a by bone
marrow mononuclear cells and T cells from aplastic anemia
patients. In our study, TNF-a expression in IMQ-treated skin
was upregulated by IL-27 injection, and was accordingly
reduced by anti-IL-27 antibody. Notably, IL-27, in synergy
with LPS, dose-dependently enhanced TNF-a production by
peritoneal macrophages in vitro. It is well known that TNF-a
is a key cytokine for the exacerbation of psoriasis, and the
blockade of TNF-a effectively reduces Th1/Th17 responses in
psoriasis (Zaba et al., 2007). Taken together, our data suggest
that IL-27 might aggravate IMQ-induced psoriasis-like skin
inflammation by inducing TNF-a overproduction, which may
lead to the activation of Th17 and Th1 responses.
In conclusion, this study supports the pivotal role of IL-27
in the regulation of T-cell responses in vivo and indicates the
accelerating effects of IL-27 in psoriasis. Although the
underlying molecular mechanisms of psoriasis pathogenesis
are complicated, IL-27 could drive Th1 immune responses
and TNF-a overproduction, and thereby exacerbate the
disease in IMQ-induced psoriasis-like skin lesions.
MATERIALS AND METHODS
Mice
Female BALB/c and C57BL/6 mice were purchased from SLC Japan
(Tokyo, Japan). Mice were 7 to 11 weeks old for all experiments and
were maintained in a specific pathogen-free barrier facility. All
studies and procedures were approved by the Committee on Animal
Experimentation of the University of Tokyo.
Reagents and antibodies
Recombinant mouse IL-27, polyclonal goat anti-mouse IL-27p28
antibody, and control goat IgG were purchased from R&D
Systems (Minneapolis, MN). Recombinant mouse IL-23 and anti-
mouse CD117 antibody were purchased from eBioscience (San
Diego, CA). Anti-mouse MHC class II, CD11c, and CD3
antibodies were from Abcam (Cambridge, UK). Fluorescein
isothiocyanate–conjugated goat IgG and Alexa Fluor 546–con-
jugated rat or hamster IgG were from Santa Cruz Biotechnology
(Santa Cruz, CA) and Invitrogen Life Technologies (Carlsbad,
CA), respectively.
Development of IL-23-induced psoriasis-like skin
inflammation
Mice were anesthetized and 20 ml of PBS, either alone or containing
500 ng of recombinant mouse IL-23, was injected intradermally into
the ears using a 27-gauge needle every other day for 16 days. At day
7 and 13, mice were killed and tissue was collected.
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Figure 6. The improvement in imiquimod (IMQ)-induced psoriasis-like skin inflammation by IL-27 antagonism. (a) Phenotypical presentation (the left four
panels) and histological analyses of mouse back skin (the right two panels) are shown. In each group, mice were injected with control IgG or anti IL-27p28
antibody (IL27p28 Ab) and IMQ was applied for 6 consecutive days. Bar¼ 20mm. (b) Clinical scores during IMQ treatment. Erythema, scaling, and thickness of
the back skin were scored on a scale from 0 to 4, and these scores were accumulated from 3 to 5 mice per group. Data are presented as means±SEs (n¼ 5).
*Po0.05 versus control IgG–injected mice with IMQ application. (c) Epidermal thickness and the number of inflammatory cell infiltrates in the dermis at day 6 of
IMQ treatment. Numbers of epidermal cell layers and dermal inflammatory cells were counted per high-power field from three to five mice per group. Data are
presented as means±SEs (n¼6). H&E, hematoxylin and eosin.
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Development of IMQ-induced psoriasis-like skin inflammation
and injection of IL-27
On the day before IMQ treatment (day 1), mice were anesthetized
and a small incision was made on the back. Osmotic minipumps
(model 1007D, Alza, Palo Alto, CA) were implanted subcutaneously
and the wound was closed. The osmotic pumps were filled with PBS,
either alone or containing recombinant mouse IL-27. The pumps
continuously delivered 400 ng of IL-27 per day subcutaneously. A
daily topical dose of 62.5mg of commercially available IMQ cream
(5%; Beselna Cream; Mochida Pharmaceuticals, Tokyo, Japan) or
control Vaseline was applied to the shaved back skin of the mice
for 6 consecutive days. In some experiments, mice were intraper-
itoneally injected with 50 mg of anti-IL-27p28 antibody or control
IgG immediately before (day 0) and 3 days after the IMQ treatment
(day 3).
Scoring of disease activity
A scoring system based on the clinical Psoriasis Area and Severity
Index, except for the affected skin area, was used (van der Fits
et al., 2009). Erythema, scaling, and thickening were scored
independently on a scale from 0 to 4: 0, none; 1, slight; 2,
moderate; 3, marked; and 4, very marked. The cumulative
score served as a measure of the severity of inflammation (scale
0–12).
Quantitative real-time reverse-transcription PCR analysis
Total RNA was isolated from mouse back skin using RNeasy fibrous
Tissue Mini kits (Qiagen, Germantown, MD) and cDNA was
synthesized using Superscript III First strand synthesis kits (Invitrogen
Life Technologies). Gene expression was quantified using the
TaqMan gene expression assay (Applied Biosystems, Warrington,
UK). All samples were analyzed in parallel for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene expression as an internal
control. The relative change in the levels of genes of interest was
determined by the 2DDCT method.
Histological analyses
Skin sections of 6mm diameter from murine back skin were
embedded in optimal cutting temperature compound, snap-frozen
in liquid nitrogen, and stored at 80 1C. Six-micrometer cryosections
of snap-frozen skin were cut using a cryostat. Sections were fixed
with cold acetone for 5minutes and stained with hematoxylin and
eosin. For the analyses of IL-27 staining, the sections were incubated
overnight at 4 1C with polyclonal goat IgG anti-mouse IL-27p28
antibody or nonimmune goat IgG. The samples were washed with
PBS and incubated with biotin-conjugated rabbit anti-goat IgG
supplied in the ABC staining kit (Vector Laboratories, Burlingame,
CA) for 2 hours at room temperature. After an additional washing
step, the samples were incubated with the Vecstatin ABC-AP
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Figure 7. Effects of IL-27 antagonism on the mRNA levels of cytokine/chemokines in imiquimod (IMQ)-treated skin.Mice were intraperitoneally injected with
anti-IL-27p28 antibody (IL27p28 Ab) or control IgG at day 0 and 3, and were daily treated with IMQ. mRNA levels in back skin at day 6 were determined by
quantitative real-time PCR for T-helper 1 (Th1) cytokine/chemokines (a), Th17 cytokine/chemokines (b), and tumor necrosis factor (TNF)-a (c). Data were
obtained from duplicate samples from five mice in each group. Values are presented as means±SEs (n¼ 10).
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reagent, followed by alkaline phosphatase substrate solution and
then counterstained with Mayer’s hematoxylin. For double staining,
the sections were first incubated overnight at 4 1C with anti-IL-27p28
antibody, followed by incubation with fluorescein isothiocyanate–-
conjugated goat IgG for 60minutes at room temperature. Subse-
quently, the sections were incubated again with anti-MHC class II,
CD11c, CD3, or CD117 overnight at 4 1C, followed by incubation
with Alexa Fluor 546–conjugated rat or hamster IgG. The nuclear
staining was performed using mounting medium with 40, 6-diamino-
2-phenylindole (Vector Laboratories).
Isolation of peritoneal macrophages and their secretion of TNF-a
Two milliliter of thioglycollate solution (3% wt/vol; Sigma Immuno-
chemicals, St Louis, MO) was injected intraperitoneally into mice,
and macrophages were obtained by washing the peritoneal cavity of
mice 2 days after thioglycollate injection. Thereafter, macrophages
were cultured with DMEM containing 5% fetal bovine serum.
Macrophages were seeded on 96-well plates at a density of
1 104 cells per well. After reaching subconfluency, the cells were
incubated with the indicated concentrations of IL-27 in 100 ml of
DMEM for 12 hours, followed by treatment with 10 ngml1 of LPS
for another 24 hours. The levels of TNF-a in the supernatants were
measured using an ELISA kit from R&D Systems according to the
manufacturer’s instructions.
Culture of keratinocytes and their secretion of TNF-a
Normal human epidermal keratinocytes were obtained from Kurabo
(Osaka, Japan) and cultured with Epilife medium, supplemented
with human keratinocyte growth supplement, 100Uml1 penicillin,
100mgml1 streptomycin, and 0.25 mgml1 amphotericin (Gibco,
Grand Island, NY). Normal human keratinocytes were seeded on
12-well plates at a density of 5 104 cells per well. After reaching
subconfluency, the cells were incubated with the indicated
concentrations of IL-27 for 24 hours. The levels of TNF-a in the
supernatants were measured using ELISA kits (R&D systems).
Statistical analyses
Data obtained are presented as means±SEs. Comparisons were
made using unpaired Student’s t-test. Values of Po0.05 were
considered to represent significant differences.
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